Q1 2013
Released May 10, 2013, after the close
10-Q filed May 10, 2013, 40 days after period end · 0001144204-13-027906
Q1 2013 · 10-Q
Revenue$102.50K$102.50K −34.4% vs Q1 2012+4,000.0% vs Q4 2012
Net Income-$3.59M-$3.59M N/M vs Q1 2012N/M vs Q4 2012
EPS Diluted-$0.05-$0.05 N/M vs Q1 2012N/M vs Q4 2012
Operating Income-$2,891,780N/M
Operating Cash Flow-$2,512,728N/M
Free Cash Flowderived-$2,514,384N/M
Margins · derived
Operating margin-2821.2%−1244.8 pt vs Q1 2012
Net margin-3502.5%−1932.7 pt vs Q1 2012
What the release said
The release
Same quarter
| Metric | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|
| Revenue | $102.50K | $156.25K | — |
| Net Income | -$3.59M | -$2.45M | -$3.10M |
| EPS Diluted | -$0.05 | -$0.05 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palisade Bio, Inc. · CIK 1357459 · Engraved from SEC EDGAR